EPIX (ESSA Pharma) Selling, General, & Admin. Expense: $17.79 Mil (TTM As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

EPIX ESSA Pharma Inc EPIX
22 GF Score
Price $0.20
View Full Analysis

What is ESSA Pharma Selling, General, & Admin. Expense?

ESSA Pharma EPIX 22 Selling, General, & Admin. Expense is $17.79 Mil as of Jun. 2025. GuruFocus rates EPIX with a GF Score™ of 22/100.

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. ESSA Pharma's selling, general, & admin. expense for the three months ended in Jun. 2025 was $5.53 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Jun. 2025 was $17.79 Mil.


ESSA Pharma  (NAS:EPIX) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


ESSA Pharma Selling, General, & Admin. Expense Related Terms


ESSA Pharma Selling, General, & Admin. Expense Historical Data

* Premium members only.

The historical data trend for ESSA Pharma's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ESSA Pharma Selling, General, & Admin. Expense Chart

ESSA Pharma Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
Selling, General, & Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.26 12.78 12.28 11.37 14.13

ESSA Pharma Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.42 3.75 4.44 4.07 5.53

EPIX vs SLXN, NLSP, PTNT: Selling, General, & Admin. Expense Comparison

For the Biotechnology subindustry, ESSA Pharma's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ESSA Pharma Selling, General, & Admin. Expense vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ESSA Pharma's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where ESSA Pharma's Selling, General, & Admin. Expense falls into.


EPIX
22GF Score
ESSA Pharma Inc EPIX
Selling, General, & Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ESSA Pharma Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $17.79 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Selling, General, & Admin. Expense of $17.79 Mil mean?
ESSA Pharma (EPIX) has a Selling, General, & Admin. Expense of $17.79 Mil as of Jun. 2025. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on ESSA Pharma and its competitors.
Is ESSA Pharma's Selling, General, & Admin. Expense too high?
ESSA Pharma's current Selling, General, & Admin. Expense is $17.79 Mil. Overall, ESSA Pharma has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does ESSA Pharma's Selling, General, & Admin. Expense compare to SLXN and NLSP?
ESSA Pharma's Selling, General, & Admin. Expense of $17.79 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Biotechnology company?
A good Selling, General, & Admin. Expense depends on the Biotechnology industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on ESSA Pharma and its competitors. ESSA Pharma's current Selling, General, & Admin. Expense is $17.79 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ESSA Pharma stock overvalued right now?
ESSA Pharma (EPIX) has a current Selling, General, & Admin. Expense of $17.79 Mil. The current Selling, General, & Admin. Expense is $17.79 Mil. ESSA Pharma's overall GF Score™ is 22/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For ESSA Pharma (EPIX), the current Selling, General, & Admin. Expense is $17.79 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ESSA Pharma Business Description

Address 999 West Broadway Street, Suite 720, Vancouver, BC, CAN, V5Z 1K5
ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.
22GF Score

Get the complete analysis for EPIX

Selling, General, & Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.20
Price